Riskpilot← Back to searchSign inGet full accessNUTRI PHARMA AS
ASActiveOrg 995765497Hammersborg Torg 3, 0179 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employeeswww.nutripharma.com
Revenue 2025
NOK 0
EBITDA margin
—
Equity ratio
77.5%
Financial strength
Net profit 2025
NOK 9K
-10% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK 0 | — |
| Net profit | NOK 9K | -10% |
| Total assets | NOK 144K | +0% |
| Equity | NOK 112K | +0% |
| Employees | 0 | — |
Legal name
NUTRI PHARMA AS
Org number
995765497
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11. august 2010
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Kommersialisering av produkter og patenter utviklet gjennom forskning på helse-effekter av soyaprodukter.
Address
Hammersborg Torg 3, 0179 Oslo
Website
www.nutripharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | −24 | 0 | 0 | −16 | 0 | 0 | 0 | −56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −24 | 0 | 0 | −16 | 0 | 0 | 0 | −56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 11 |
| Profit before tax | 0 | −24 | 0 | 0 | −16 | 0 | −1 | 0 | −56 | 0 | 0 | 0 | 0 | 0 | 12 | 11 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | 32 | −0 | −0 | −63 | −0 | −0 | 3 | 2 |
| Net profit | 0 | −24 | 0 | 0 | −16 | 0 | −1 | 0 | −88 | 0 | 0 | 63 | 0 | 0 | 10 | 9 |
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 113 | 100 | — | — | 25 | 25 | 24 | 24 | −8 | −32 | −32 | 32 | 144 | 144 | 144 | 144 |
| Equity | 100 | 76 | — | — | 25 | 25 | 24 | 24 | −64 | −64 | −64 | −1 | 112 | 112 | 112 | 112 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Total debt | 12 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20102025
Equity ratio
77.5%
This company
38.2%
Market median
+103% vs market
20102025
Return on equity
7.7%
This company
18.4%
Market median
-58% vs market
20102025
Net profit margin
858000.0%
This company
8.1%
Market median
+10592493% vs market
20102025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20102025
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20102025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-07-01 – 2010-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Solon Eiendom As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Solon Eiendom Holding As
NUTRI PHARMA AS Board members of NUTRI PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Forseth Helgesen | Board of Directors | 0 companies |
| Jørgen Stavrum | Chairman | 0 companies |
| Andreas Martinussen | Chairman | 0 companies |
| Ole Halvor Svenkerud | Chairman | 0 companies |